Edition:
United States

GlaxoSmithKline PLC (GSK.L)

GSK.L on London Stock Exchange

1,688.00GBp
11:42am EDT
Change (% chg)

-11.50p (-0.68%)
Prev Close
1,699.50p
Open
1,702.00p
Day's High
1,708.00p
Day's Low
1,687.50p
Volume
9,360,888
Avg. Vol
8,753,649
52-wk High
1,716.50p
52-wk Low
1,210.27p

Latest Key Developments (Source: Significant Developments)

GlaxoSmithkline accelerates filing of COPD triple-therapy drug
Thursday, 2 Jun 2016 02:00am EDT 

Glaxosmithkline Plc : Regulatory update on us filing plans for closed triple combination therapy ff/umec/vi in patients with copd .Acceleration of filing of us new drug application now expected by end of 2016.  Full Article

Regulus expands clinical trial collaboration with GSK
Wednesday, 1 Jun 2016 08:00am EDT 

Regulus Therapeutics Inc : Ongoing phase ii rg-101 and oral gsk2878175 combination study on track to report interim results by year-end .Regulus expands clinical trial collaboration with gsk.  Full Article

Fitch downgrades GSK to 'A' with stable outlook
Friday, 27 May 2016 11:38am EDT 

Fitch: Fitch downgrades GSK to 'A', outlook stable . Downgrade reflects fitch's view of a weakening business risk profile for GlaxoSmithKline PLC . Has also downgraded senior unsecured rating for debt issued under Glaxosmithkline Capital PLC to 'A' from 'A+' .Has assigned a senior unsecured rating of 'A' to debt issued by GlaxoSmithKline Capital Inc.  Full Article

GlaxoSmithKline appoints Vivienne Cox to board
Friday, 27 May 2016 09:56am EDT 

Glaxosmithkline Plc : Board and committee changes .Dr Vivienne Cox, CBE, has been appointed to board of company as a non-executive director with effect from 1 July 2016.  Full Article

GSK says gene therapy for immune disorder meets main goal
Wednesday, 25 May 2016 05:09am EDT 

Glaxosmithkline Plc : Key efficacy endpoint for analysis was survival. All 18 patients were alive after a median follow-up of 6.9 years at data cut on 8th may 2014 . Immune reconstitution was observed from six months post-treatment for majority of patients, and was sustained over .Overall safety findings in study were in line with expectations.  Full Article

Glaxosmithkline and Innoviva report positive headline results in Salford Lung study
Tuesday, 24 May 2016 05:54am EDT 

Glaxosmithkline Plc : Co and Innoviva announced positive headline results from innovative salford lung study in chronic obstructive pulmonary disease . Study showed that relvar ® ellipta ® 100/25mcg achieved a superior reduction in exacerbations versus usual care, in patients with copd . Analyses remain ongoing and will be subject of future publications and presentations . Second salford lung study is currently being conducted in asthma patients, with results expected in 2017 .For primary effectiveness analysis, in patients treated there was statistically significant reduction in rate of moderate or severe exacerbations.  Full Article

GSK says its meningitis vaccine achieves study goals
Friday, 13 May 2016 06:15am EDT 

GlaxoSmithKline Plc : GSK's Bexsero achieves primary and secondary endpoints with reduced 3-dose schedule (2+1) in safety and immunogenicity study in infants and children . Believe that these initial study results may support a reduced dosing schedule, which could mean fewer shots for infants - chief medical officer vaccines Further company coverage: [GSK.L] (Bengaluru Newsroom: +91 806 749 1136).  Full Article

Valneva signs new research and development collaboration with GlaxoSmithKline
Monday, 8 Feb 2016 01:00am EST 

Valneva SE:Signs new research and development collaboration with GlaxoSmithKline for EB66 cell line​.To supply process development services for EB66 -based influenza vaccines.Advanced development program sponsored by the US department of health and human services.Is entitled to receive milestone payments as well as royalties associated with future sales‍​.‍To receive research fees under the new agreement.  Full Article

Glaxosmithkline plc Nucala receives approval from US FDA
Thursday, 5 Nov 2015 02:00am EST 

GlaxoSmithKline plc:Says that it has received approval from US Food and Drug Administration (FDA) for its Biologics License Application (BLA) for Nucala (mepolizumab) as an add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype.Says Nucala is not approved for treatment of other eosinophilic conditions or relief of acute bronchospasm or status asthmaticus.  Full Article

Pfizer Inc completes acquisition of nimenrix and mencevax from GlaxoSmithKline Plc
Thursday, 1 Oct 2015 08:00am EDT 

Pfizer Inc:Says that it has completed acquisition of GlaxoSmithKline's quadrivalent meningococcal ACWY vaccines Nimenrix and Mencevax.  Full Article

PRESS DIGEST- British Business - July 28

July 28 The following are the top stories on the business pages of British newspapers. Reuters has not verified these stories and does not vouch for their accuracy.